Development of Cancer Gene Therapy with REIC/Dkk-3

KUMON, Hiromi

/Graduate School of Medicine, Dentistry and Pharmaceutical Sciences/Professor/ kumon[at]md.okayama-u.ac.jp

The REIC/Dkk-3 gene was isolated at Okayama University and found to be a new tumor suppressor gene. The expression of REIC is significantly reduced in a wide variety of cancer cells and its forced expression using adenoviral vector (Ad-REIC) induces cancer selective apoptosis and enhances personalized anti-cancer immunology by inducing CTL and activating NK cells. The second generation, Ad-SGE-REIC, is on the verge of completing Phase I for prostate cancer in the US by Momotaro-Gene Inc., biotech spinoff company from Okayama University and will soon be in the Phase I for malignant mesothelioma in Japan by KYORIN Pharmaceutical.

References: Nature, Scientific Reports, PRL and JACS papers were published by members of RCNFM in 2010 -2015.See web site.

Return

REIC is a tumor suppressor gene and down-regulated in a wide variety of cancer cells ⇒ Almost all solid cancers can be targeted